Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allosterically modulate γ-secretase, reducing the net production of Aβ42 and to a lesser extent Aβ40, while concomitantly augmenting production of Aβ38 and Aβ37. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a >40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of Aβ42 in rat brain by 50%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








![Figure 9. Efficacy of GSM compound 2 on various Aβ peptide levels in plasma of NHPs. (A) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/dose) at 4 h following a single nasogastric dose of 0 mg/kg (vehicle), 10 mg/kg (mean plasma [drug] = 753 ng/ml), 30 mg/kg (mean plasma [drug] = 1,235 ng/ml), 100 mg/kg (mean plasma [drug] = 2,895 ng/ml), or 200 mg/kg (mean plasma [drug] = 2,475 ng/ml). (B) Plasma levels of Aβ38, Aβ40, and Aβ42 in male and female NHPs (n = 4/time point) following a single nasogastric dose (200 mg/kg) on day 1 of the repeat-dosing phase in the DRF toxicokinetic study measured at 0 h (mean plasma [drug] = LLOQ), 1 h (mean plasma [drug] = 109 ng/ml), 2 h (mean plasma [drug] = 460 ng/ml), 4 h (mean plasma [drug] = 2,300 ng/ml), 8 h (mean plasma [drug] = 2,560 ng/ml), or 24 h (mean plasma [drug] = 1,705 ng/ml) after drug or vehicle administration. Aβ38, Aβ40, and Aβ42 peptides were quantitated using Meso Scale Sector 6000 Multiplex assays. Data are expressed as picograms per milliliter. Statistical analysis was performed using GraphPad Prism software, and results are expressed as mean ± SEM. ANOVA was used to detect a significant effect. *, P < 0.05; **, P < 0.01; ***, P < 0.001.](https://figures.cochat.ai/paper-figures/60a7435996c54d4fa835989c1dafa877/preclinical-validation-of-a-potent-secretase-modulator-for-alzheimers-disease-figure-9.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [548]
The cited source says what the claim attributes to it.
In the citing paper
“Allosteric modulators of γ-secretase encourage the production of shorter, less toxic Aβ subtypes, and even potentially minimize effects on Notch and some other substrates. Some γ-secretase modulators (GSMs) also exhibited promising safety outcomes in preclinical studies and clinical trials.546–548”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [548]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., et al. (1999) · Nature · doi:10.1038/19083 · Cited by 2,100
The Ames Salmonella/microsome mutagenicity assay
Mortelmans, K., & Zeiger, E. (2000) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(00)00064-6 · Cited by 2,098
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410 · cited 1×
“BACE-1 inhibition (Vassar, 2014) represents a similar approach to reduce generation of all Aβ peptide species, but recent clinical trials of BACE-1 inhibitors in mild to moderate and prodromal AD were terminated prematurely because of drug-related adverse events and lack of efficacy (Egan et al.,…”
ResultCoric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
Fleisher, A. S., Raman, R., Siemers, E. R., Becerra, L., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332
Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., & Van Broeckhoven, C. (2006) · Human Mutation · doi:10.1002/humu.20336 · Cited by 323
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314
Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M., Fak, J., Olsen, O., Darnell, R. B., & Tessier-Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.010 · Cited by 304
Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050902 · Cited by 262
Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., Ahn, K., Nguyen, P., Comer, D., Mao, L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.018 · Cited by 252
Self-citationTargeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, V., Salloway, S., van Dyck, C. H., Dubois, B., Andreasen, N., Brody, M., Curtis, C., Soininen, H., Thein, S., Shiovitz, T., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0607 · Cited by 240
Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer’s Disease
Henley, D., Raghavan, N., Sperling, R., Aisen, P., Raman, R., & Romano, G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1813435 · Cited by 197
The bacterial tryptophan reverse mutation assay with Escherichia coli WP2
Mortelmans, K. E., & Riccio, E. S. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00076-2 · Cited by 144
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S. M., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139
Liu, Q., Waltz, S., Woodruff, G., Ouyang, J., Israel, M. A., Herrera, C., Sarsoza, F., Tanzi, R. E., Koo, E. H., Ringman, J. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2482 · Cited by 91
Self-citationLowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
Knopman, D. S. (2019) · New England Journal of Medicine · doi:10.1056/nejme1903193 · Cited by 69 · cited 1×
“…et al., 2012; Doody et al., 2013) or BACE inhibitors (Egan et al., 2018; Salloway et al., 2014; Sevigny et al., 2016) and exposed intolerable side effect profiles and, in most cases, appeared to cause cognitive worsening relative to placebo (Coric et al., 2015; Doody et al., 2013; Knopman, 2019).”
BackgroundWagner, S. L., Zhang, C., Cheng, S., Nguyen, P., Zhang, X., Rynearson, K. D., Wang, R., Li, Y., Sisodia, S. S., Mobley, W. C., et al. (2014) · Biochemistry · doi:10.1021/bi401537v · Cited by 50
Self-citationPharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606
Wagner, S. L., Rynearson, K. D., Duddy, S. K., Zhang, C., Nguyen, P. D., Becker, A., Vo, U., Masliah, D., Monte, L., Klee, J. B., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240861 · Cited by 49
Self-citationWard, K. W., Stelman, G. J., Morgan, J. A., Zeigler, K. S., Azzarano, L. M., Kehler, J. R., McSurdy-Freed, J. E., Proksch, J. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.2.172 · Cited by 47
Soares, H. D., Gasior, M., Toyn, J. H., Wang, J.-S., Hong, Q., Berisha, F., Furlong, M. T., Raybon, J., Lentz, K. A., Sweeney, F., et al. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232256 · Cited by 46
Yu, Y., Logovinsky, V., Schuck, E., Kaplow, J., Chang, M.-K., Miyagawa, T., Wong, N., & Ferry, J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.249 · Cited by 43
Ahn, J. E., Carrieri, C., Dela Cruz, F., Fullerton, T., Hajos‐Korcsok, E., He, P., Kantaridis, C., Leurent, C., Liu, R., Mancuso, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1570 · Cited by 36
Toyn, J. H., Boy, K. M., Raybon, J. J., Meredith, J. E., Robertson, A. S., Guss, V. L., Hoque, N., Sweeney, F., Zhuo, X., Clarke, W., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232249 · Cited by 27
Potential Use of γ-Secretase Modulators in the Treatment of Alzheimer Disease
Wagner, S. L., Tanzi, R. E., Mobley, W. C., & Galasko, D. R. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.540 · Cited by 22
Self-citationMabuchi, H., Haba, T., TATAMI, R., Miyamoto, S., Sakai, Y., WAKASUGI, T., Watanabe, A., Koizumi, J., & Takeda, R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.023 · Cited by 21
Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme
Rynearson, K. D., Buckle, R. N., Barnes, K. D., Herr, R. J., Mayhew, N. J., Paquette, W. D., Sakwa, S. A., Nguyen, P. D., Johnson, G., Tanzi, R. E., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.011 · Cited by 20
Self-citationThe GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer’s Disease
Prikhodko, O., Rynearson, K. D., Sekhon, T., Mante, M., Nguyen, P. D., Rissman, R. A., Tanzi, R. E., & Wagner, S. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190442 · Cited by 18
Self-citationDesign and synthesis of novel methoxypyridine-derived gamma-secretase modulators
Rynearson, K. D., Buckle, R. N., Herr, R. J., Mayhew, N. J., Chen, X., Paquette, W. D., Sakwa, S. A., Yang, J., Barnes, K. D., Nguyen, P. A. H., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115734 · Cited by 12
Self-citationKounnas, M. Z., Durakoglugil, M. S., Herz, J., & Comer, W. T. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.006 · Cited by 11
In Vivo Pig‐a gene mutation assay: Guidance for 3Rs‐friendly implementation
Raschke, M., Igl, B., Kenny, J. D., Collins, J. E., Dertinger, S. D., Labash, C., Bhalli, J. A., Tebbe, C. C., McNeil, K. M., & Sutter, A. P. (2016) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22060 · Cited by 10
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
γ-Secretase in Alzheimer’s disease
Hur, J.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 310
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Self-citationThe case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
Metadata
- Authors
- Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., Florio, J., Mante, M., Salehi, B., Arias, C., Galasko, D., Head, B. P., Johnson, G., Lin, J. H., Duddy, S. K., Rissman, R. A., Mobley, W. C., Thinakaran, G., Tanzi, R. E., & Wagner, S. L.
- Affiliations
- University of California San Diego (US)
- University of South Florida (US)
- Massachusetts General Hospital (US)
- Veterans Health Administration (US)
- NuPharmAdvise, Sanbornton, NH 6
- Seven (CZ)
- Integrated Nonclinical Development Solutions (United States) (US)
- Corresponding author
- Wagner, Steven L.
- ORCID
- Rynearson, Kevin D.
- Ponnusamy, Moorthi
- Prikhodko, Olga
- Xie, Yuhuan
- Zhang, Can
- Nguyen, Phuong
- Hug, Brenda
- Sawa, Mariko
- Becker, Ann
- Spencer, Brian
- Florio, Jazmin
- Mante, Michael
- Salehi, Bahar
- Arias, Carlos
- Galasko, Douglas
- Head, Brian P.
- Johnson, Graham
- Lin, Jiunn H.
- Duddy, Steven K.
- Rissman, Robert A.
- Mobley, William C.
- Thinakaran, Gopal
- Tanzi, Rudolph E.
- Wagner, Steven L.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2021-03-02
- Volume
- 218
- Issue
- 4
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7931646
- OpenAlex
- W3135208068
- Cited by
- 76
- References
- 46
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 17 · 2021: 11
- FWCI
- 10.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Funders
- Cure Alzheimer’s Fund
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging (NS 074501, U01AG048986, R01AG055523, R01AG054223, R01AG056061)
- National Institutes of Health
- Chen Foundation (R-86U55A)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- γ-secretase modulators, Alzheimer's disease prevention, early-onset familial Alzheimer's disease, amyloid-beta 42, gamma-secretase inhibitors, allosteric modulation, transgenic mouse model, preclinical safety, dose-dependent efficacy, primary prevention
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Female, Humans, Macaca fascicularis, Male, Mice, Inbred C57BL, Mice, Transgenic, Neuroblastoma, Peptide Fragments, Phenethylamines, Pyridazines, Signal Transduction, Amyloid beta-Peptides, Treatment Outcome, Rats, Sprague-Dawley, Cell Line, Tumor, Mice, Rats, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.